Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 37 to 48 of 230 entries
Sorted by: Best Match Show Resources per page
WHO report on drug development marred by big pharma leak.

Nature medicine

Mullard A.
PMID: 20134436
Nat Med. 2010 Feb;16(2):133. doi: 10.1038/nm0210-133.

No abstract available.

Cite
Mullard A. WHO report on drug development marred by big pharma leak. Nat Med. 2010;16(2):133doi: 10.1038/nm0210-133.
Mullard, A. (2010). WHO report on drug development marred by big pharma leak. Nature medicine, 16(2), 133. https://doi.org/10.1038/nm0210-133
Mullard, Asher. "WHO report on drug development marred by big pharma leak." Nature medicine vol. 16,2 (2010): 133. doi: https://doi.org/10.1038/nm0210-133
Mullard A. WHO report on drug development marred by big pharma leak. Nat Med. 2010 Feb;16(2):133. doi: 10.1038/nm0210-133. PMID: 20134436.
Copy Download .nbib Format: NLM
Diseases as network perturbations.

Current opinion in biotechnology

del Sol A, Balling R, Hood L, Galas D.
PMID: 20709523
Curr Opin Biotechnol. 2010 Aug;21(4):566-71. doi: 10.1016/j.copbio.2010.07.010. Epub 2010 Aug 13.

The tremendous amount of the data obtained from the study of complex biological systems changes our view on the pathogenesis of human diseases. Instead of looking at individual components of biological processes, we focus our attention more on the...

Cite
del Sol A, Balling R, Hood L, et al. Diseases as network perturbations. Curr Opin Biotechnol. 2010;21(4):566-71doi: 10.1016/j.copbio.2010.07.010.
del Sol, A., Balling, R., Hood, L., & Galas, D. (2010). Diseases as network perturbations. Current opinion in biotechnology, 21(4), 566-71. https://doi.org/10.1016/j.copbio.2010.07.010
del Sol, Antonio, et al. "Diseases as network perturbations." Current opinion in biotechnology vol. 21,4 (2010): 566-71. doi: https://doi.org/10.1016/j.copbio.2010.07.010
del Sol A, Balling R, Hood L, Galas D. Diseases as network perturbations. Curr Opin Biotechnol. 2010 Aug;21(4):566-71. doi: 10.1016/j.copbio.2010.07.010. Epub 2010 Aug 13. PMID: 20709523.
Copy Download .nbib Format: NLM
Devil in the details.

Nature medicine

[No authors listed]
PMID: 18256601
Nat Med. 2008 Feb;14(2):105-6. doi: 10.1038/nm0208-105.

No abstract available.

Cite
Devil in the details. Nat Med. 2008;14(2):105-6doi: 10.1038/nm0208-105.
(2008). Devil in the details. Nature medicine, 14(2), 105-6. https://doi.org/10.1038/nm0208-105
"Devil in the details." Nature medicine vol. 14,2 (2008): 105-6. doi: https://doi.org/10.1038/nm0208-105
Devil in the details. Nat Med. 2008 Feb;14(2):105-6. doi: 10.1038/nm0208-105. PMID: 18256601.
Copy Download .nbib Format: NLM
Three-dimensional printing in pharmaceutics: promises and problems.

Journal of pharmaceutical sciences

Yu DG, Zhu LM, Branford-White CJ, Yang XL.
PMID: 18257041
J Pharm Sci. 2008 Sep;97(9):3666-90. doi: 10.1002/jps.21284.

Three-dimensional printing (3DP) is a rapid prototyping (RP) technology. Prototyping involves constructing specific layers that uses powder processing and liquid binding materials. Reports in the literature have highlighted the many advantages of the 3DP system over other processes in...

Cite
Yu DG, Zhu LM, Branford-White CJ, et al. Three-dimensional printing in pharmaceutics: promises and problems. J Pharm Sci. 2008;97(9):3666-90doi: 10.1002/jps.21284.
Yu, D. G., Zhu, L. M., Branford-White, C. J., & Yang, X. L. (2008). Three-dimensional printing in pharmaceutics: promises and problems. Journal of pharmaceutical sciences, 97(9), 3666-90. https://doi.org/10.1002/jps.21284
Yu, Deng Guang, et al. "Three-dimensional printing in pharmaceutics: promises and problems." Journal of pharmaceutical sciences vol. 97,9 (2008): 3666-90. doi: https://doi.org/10.1002/jps.21284
Yu DG, Zhu LM, Branford-White CJ, Yang XL. Three-dimensional printing in pharmaceutics: promises and problems. J Pharm Sci. 2008 Sep;97(9):3666-90. doi: 10.1002/jps.21284. PMID: 18257041.
Copy Download .nbib Format: NLM
Efficient medicinal chemistry.

Combinatorial chemistry & high throughput screening

Kyle DJ.
PMID: 16475964
Comb Chem High Throughput Screen. 2006 Feb;9(2):77. doi: 10.2174/138620706775541909.

No abstract available.

Cite
Kyle DJ. Efficient medicinal chemistry. Comb Chem High Throughput Screen. 2006;9(2):77doi: 10.2174/138620706775541909.
Kyle, D. J. (2006). Efficient medicinal chemistry. Combinatorial chemistry & high throughput screening, 9(2), 77. https://doi.org/10.2174/138620706775541909
Kyle, Donald J. "Efficient medicinal chemistry." Combinatorial chemistry & high throughput screening vol. 9,2 (2006): 77. doi: https://doi.org/10.2174/138620706775541909
Kyle DJ. Efficient medicinal chemistry. Comb Chem High Throughput Screen. 2006 Feb;9(2):77. doi: 10.2174/138620706775541909. PMID: 16475964.
Copy Download .nbib Format: NLM
Nurturing European collaboration.

Nature reviews. Drug discovery

[No authors listed]
PMID: 18591973
Nat Rev Drug Discov. 2008 Jul;7(7):548-9. doi: 10.1038/nrd2634.

No abstract available.

Cite
Nurturing European collaboration. Nat Rev Drug Discov. 2008;7(7):548-9doi: 10.1038/nrd2634.
(2008). Nurturing European collaboration. Nature reviews. Drug discovery, 7(7), 548-9. https://doi.org/10.1038/nrd2634
"Nurturing European collaboration." Nature reviews. Drug discovery vol. 7,7 (2008): 548-9. doi: https://doi.org/10.1038/nrd2634
Nurturing European collaboration. Nat Rev Drug Discov. 2008 Jul;7(7):548-9. doi: 10.1038/nrd2634. PMID: 18591973.
Copy Download .nbib Format: NLM
Multiplicity and flexibility in clinical trials.

Pharmaceutical statistics

Brannath W, Koenig F, Bauer P.
PMID: 17674349
Pharm Stat. 2007 Jul-Sep;6(3):205-16. doi: 10.1002/pst.302.

Flexible designs offer a large amount of flexibility in clinical trials with control of the type I error rate. This allows the combination of trials from different clinical phases of a drug development process. Such combinations require designs where...

Cite
Brannath W, Koenig F, Bauer P. Multiplicity and flexibility in clinical trials. Pharm Stat. 2007;6(3):205-16doi: 10.1002/pst.302.
Brannath, W., Koenig, F., & Bauer, P. (2007). Multiplicity and flexibility in clinical trials. Pharmaceutical statistics, 6(3), 205-16. https://doi.org/10.1002/pst.302
Brannath, Werner, et al. "Multiplicity and flexibility in clinical trials." Pharmaceutical statistics vol. 6,3 (2007): 205-16. doi: https://doi.org/10.1002/pst.302
Brannath W, Koenig F, Bauer P. Multiplicity and flexibility in clinical trials. Pharm Stat. 2007 Jul-Sep;6(3):205-16. doi: 10.1002/pst.302. PMID: 17674349.
Copy Download .nbib Format: NLM
Network analyses in systems pharmacology.

Bioinformatics (Oxford, England)

Berger SI, Iyengar R.
PMID: 19648136
Bioinformatics. 2009 Oct 01;25(19):2466-72. doi: 10.1093/bioinformatics/btp465. Epub 2009 Jul 30.

Systems pharmacology is an emerging area of pharmacology which utilizes network analysis of drug action as one of its approaches. By considering drug actions and side effects in the context of the regulatory networks within which the drug targets...

Cite
Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics. 2009;25(19):2466-72doi: 10.1093/bioinformatics/btp465.
Berger, S. I., & Iyengar, R. (2009). Network analyses in systems pharmacology. Bioinformatics (Oxford, England), 25(19), 2466-72. https://doi.org/10.1093/bioinformatics/btp465
Berger, Seth I, and Iyengar, Ravi. "Network analyses in systems pharmacology." Bioinformatics (Oxford, England) vol. 25,19 (2009): 2466-72. doi: https://doi.org/10.1093/bioinformatics/btp465
Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics. 2009 Oct 01;25(19):2466-72. doi: 10.1093/bioinformatics/btp465. Epub 2009 Jul 30. PMID: 19648136; PMCID: PMC2752618.
Copy Download .nbib Format: NLM
Human metabolic network reconstruction and its impact on drug discovery and development.

Drug discovery today

Ma H, Goryanin I.
PMID: 18468557
Drug Discov Today. 2008 May;13(9):402-8. doi: 10.1016/j.drudis.2008.02.002. Epub 2008 Mar 24.

This paper describes the process for the reconstruction of a high quality human metabolic network from the genome information, the existing problems in the reconstruction and why a time-consuming literature based consolidation process is needed. The reconstructed metabolic network...

Cite
Ma H, Goryanin I. Human metabolic network reconstruction and its impact on drug discovery and development. Drug Discov Today. 2008;13(9):402-8doi: 10.1016/j.drudis.2008.02.002.
Ma, H., & Goryanin, I. (2008). Human metabolic network reconstruction and its impact on drug discovery and development. Drug discovery today, 13(9), 402-8. https://doi.org/10.1016/j.drudis.2008.02.002
Ma, Hongwu, and Goryanin, Igor. "Human metabolic network reconstruction and its impact on drug discovery and development." Drug discovery today vol. 13,9 (2008): 402-8. doi: https://doi.org/10.1016/j.drudis.2008.02.002
Ma H, Goryanin I. Human metabolic network reconstruction and its impact on drug discovery and development. Drug Discov Today. 2008 May;13(9):402-8. doi: 10.1016/j.drudis.2008.02.002. Epub 2008 Mar 24. PMID: 18468557.
Copy Download .nbib Format: NLM
Paediatric drug development and clinical trials.

Advances in experimental medicine and biology

McIntosh ED.
PMID: 19280857
Adv Exp Med Biol. 2009;634:153-9. doi: 10.1007/978-0-387-79838-7_14.

No abstract available.

Cite
McIntosh ED. Paediatric drug development and clinical trials. Adv Exp Med Biol. 2009;634:153-9doi: 10.1007/978-0-387-79838-7_14.
McIntosh, E. D. (2009). Paediatric drug development and clinical trials. Advances in experimental medicine and biology, 634153-9. https://doi.org/10.1007/978-0-387-79838-7_14
McIntosh, E David G. "Paediatric drug development and clinical trials." Advances in experimental medicine and biology vol. 634 (2009): 153-9. doi: https://doi.org/10.1007/978-0-387-79838-7_14
McIntosh ED. Paediatric drug development and clinical trials. Adv Exp Med Biol. 2009;634:153-9. doi: 10.1007/978-0-387-79838-7_14. PMID: 19280857.
Copy Download .nbib Format: NLM
Extremal problems for topological indices in combinatorial chemistry.

Journal of computational biology : a journal of computational molecular cell biology

Tichy RF, Wagner S.
PMID: 16201918
J Comput Biol. 2005 Sep;12(7):1004-13. doi: 10.1089/cmb.2005.12.1004.

Topological indices of molecular graphs are related to several physicochemical characteristics; recently, the inverse problem for some of these indices has been studied, and it has some applications in the design of combinatorial libraries for drug discovery. It is...

Cite
Tichy RF, Wagner S. Extremal problems for topological indices in combinatorial chemistry. J Comput Biol. 2005;12(7):1004-13doi: 10.1089/cmb.2005.12.1004.
Tichy, R. F., & Wagner, S. (2005). Extremal problems for topological indices in combinatorial chemistry. Journal of computational biology : a journal of computational molecular cell biology, 12(7), 1004-13. https://doi.org/10.1089/cmb.2005.12.1004
Tichy, Robert F, and Wagner, Stephan. "Extremal problems for topological indices in combinatorial chemistry." Journal of computational biology : a journal of computational molecular cell biology vol. 12,7 (2005): 1004-13. doi: https://doi.org/10.1089/cmb.2005.12.1004
Tichy RF, Wagner S. Extremal problems for topological indices in combinatorial chemistry. J Comput Biol. 2005 Sep;12(7):1004-13. doi: 10.1089/cmb.2005.12.1004. PMID: 16201918.
Copy Download .nbib Format: NLM
Visualization concepts to enhance quantitative decision making in drug development.

Journal of clinical pharmacology

Dykstra K, Pugh R, Krause A.
PMID: 20881226
J Clin Pharmacol. 2010 Sep;50(9):130S-139S. doi: 10.1177/0091270010376969.

Communication of analysis and simulation results via graphical presentation is a cornerstone of pharmacometric analysis. A modeling and simulation (M&S) project typically has 3 distinct phases: (1) exploratory data analysis, (2) model building, and (3) simulation. Each phase has...

Cite
Dykstra K, Pugh R, Krause A. Visualization concepts to enhance quantitative decision making in drug development. J Clin Pharmacol. 2010;50(9):130S-139Sdoi: 10.1177/0091270010376969.
Dykstra, K., Pugh, R., & Krause, A. (2010). Visualization concepts to enhance quantitative decision making in drug development. Journal of clinical pharmacology, 50(9), 130S-139S. https://doi.org/10.1177/0091270010376969
Dykstra, Kevin, et al. "Visualization concepts to enhance quantitative decision making in drug development." Journal of clinical pharmacology vol. 50,9 (2010): 130S-139S. doi: https://doi.org/10.1177/0091270010376969
Dykstra K, Pugh R, Krause A. Visualization concepts to enhance quantitative decision making in drug development. J Clin Pharmacol. 2010 Sep;50(9):130S-139S. doi: 10.1177/0091270010376969. PMID: 20881226.
Copy Download .nbib Format: NLM
Showing 37 to 48 of 230 entries